We feature an interview in this issue with Professor Eva Semotanová, director of the Institute of History of the ASC R. As a research worker, she specializes in interdisciplinary fields of science on the intersection between geography and history, namely, historical geography, history of cartography and historical cartography. Professor Semotanová's study includes the history of Czech towns and cities in a historical-geographic context as she seeks to integrate this context into historical processes. She supervises the Institute's cartographic collection. Chair of the Committee for Historical Geography, she also lectures on historical geography. and Marina Hužvárová.
Studie, shrnující dějiny knihovny, založené původně při Ústavu pro hudební vědu ČSAV a nyní spravované Kabinetem hudební historie EÚ AV ČR, její poslání a základní funkce., Jana Vozková., Rubrika: Informatorium, and Cizojazyčné resumé není.
The European Southern Observatory (ESO) celebrates fifty years since the signing of its founding convention. Over the last half century, ESO has become the world's most productive ground-based astronomical observatory. The signing of the ESO Convention on October, 5, 1962 and the foundation of ESO was the culmination of the vision of leading astronomers from five European countries: Belgium, France, Germany, the Netherlands and Sweden. They had decided to join forces for the purpose of building a large telescope that would give them access to the magnificent and rich southern sky. Operating three unique and world-class observing sites in Chile (at La Silla, Paranal and Chajnantor), ESO has become a leader in the astronomical research community. To celebrate the 50th anniversary, ESO and its partners (including the Czech Republic) are organising many events and public initiatives during 2012. and Marina Hužvárová.
A firm called Company RadioMedic Ltd., developed at the Nuclear Physics Institute of the ASCR in 2009, deals with the development, manufacturing and distribu‑ tion of radiopharmaceutical preparations. It has developed a ra-diopharmaceutical with an active substance that selectively binds to hypoxic cells. These tumor cells are more sensitive to radiotherapy and chemotherapy in the presence of oxygen in tissue and consequently the number of the hypoxic cells is a limiting factor for a therapy effect. and František Melichar.